Nyxoah S.A. (NYXH)
NASDAQ: NYXH · Real-Time Price · USD
8.33
+0.05 (0.60%)
Nov 21, 2024, 12:13 PM EST - Market open
Company Description
Nyxoah S.A., a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions.
The company’s lead solution comprises Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea.
Nyxoah S.A. was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.
Nyxoah S.A.
| Country | Belgium |
| Founded | 2009 |
| IPO Date | Jul 2, 2021 |
| Industry | Medical Instruments & Supplies |
| Sector | Healthcare |
| Employees | 147 |
| CEO | Olivier Taelman |
Contact Details
Address: Rue Edouard Belin 12 Mont-Saint-Guibert, 1435 Belgium | |
| Phone | 32 10 22 23 55 |
| Website | nyxoah.com |
Stock Details
| Ticker Symbol | NYXH |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | EUR |
| IPO Price | $30.00 |
| CIK Code | 0001857190 |
| ISIN Number | BE0974358906 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| Olivier Taelman | Chief Executive Officer and Executive Director |
| Robert Taub MBA | Co-Founder and Chairman |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 20, 2024 | 6-K | Report of foreign issuer |
| Nov 18, 2024 | 6-K | Report of foreign issuer |
| Nov 8, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| Nov 6, 2024 | 6-K | Report of foreign issuer |
| Nov 5, 2024 | 6-K | Report of foreign issuer |
| Oct 28, 2024 | 6-K | Report of foreign issuer |
| Oct 15, 2024 | 6-K | Report of foreign issuer |
| Oct 10, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Oct 9, 2024 | 6-K | Report of foreign issuer |
| Oct 7, 2024 | 6-K | Report of foreign issuer |